3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
10
Other solid neoplasm
7
CNS
7
Gastrointestinal
6
Dermatologic
6
Tumor-Agnostic
4
Genitourinary
2
Breast
2
Head & Neck
1
Endocrine
1
Conditions
Differentiated Thyroid Cancer
1
Interventions
Everolimus
23
pasireotide
14
lutetium Lu 177 dotatate
10
Octreotide
10
lanreotide
9
surufatinib
8
Carboplatin
8
Paclitaxel
7
pembrolizumab
5
amino-acid, glucose, and electrolyte solution
5
Thyrotropin Alfa
5
Sunitinib
5
Nivolumab
5
Injections
5
3-Iodobenzylguanidine
5
relacorilant
4
fosbretabulin
4
Temozolomide
4
Fulvestrant
4
Etoposide
4
Data Collection
4
Cisplatin
4
vandetanib
3
selpercatinib
3
dabrafenib
3
anlotinib
3
Mifepristone
3
Lutetium-177
3
Lutetium
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
AZD 6244
×
Endocrine
×
Clear all
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts